Osteoporosis in Women

This piece is for general information and discussion only. It is not medical or legal advice.

1. Context and why the issue matters

Osteoporosis is a long‑term condition in which reduced bone strength increases the likelihood of fractures from relatively low‑impact injuries. Women experience the condition earlier and more frequently than men, largely due to hormonal changes across the life course and longstanding patterns of under‑diagnosis. Hip, spine and wrist fractures are particularly common in women, and vertebral fractures may occur without a clear injury. National datasets show that fragility fractures carry substantial consequences for independence, quality of life and mortality.

Reports across the NHS and wider public bodies describe delays in recognising fracture risk, inconsistent access to bone density scanning and wide variation in follow‑up after fractures. These themes align with broader patterns often noted in women’s health: symptoms being reframed as stress, age or lifestyle, inconsistent attention to perimenopause and menopause, and communication gaps across clinical teams.

2. Evidence and policy

Safe and consistent care in England is shaped by several national frameworks.

NICE

The National Institute for Health and Care Excellence publishes guidance on assessing fracture risk, using tools such as FRAX or QFracture, and considering bone density scanning when appropriate. Guidance outlines risk factors that clinicians typically assess, including age, previous fractures, early menopause, family history, low body weight, corticosteroid use, smoking, alcohol intake and long‑term conditions affecting mobility. NICE also describes expectations for prescribing and reviewing osteoporosis medication. These documents act as the baseline for consistent case‑finding and treatment.

Fracture Liaison Services (FLS)

A Fracture Liaison Service is an NHS service intended to identify adults who experience a fracture, investigate underlying osteoporosis and organise follow‑up. Evidence shows that well‑structured FLS pathways reduce the chance of further fractures by ensuring assessment, scanning when indicated and appropriate treatment. Despite this, national audits continue to describe gaps in referral, communication and monitoring, with coverage varying between NHS organisations.

Origin of the FLS model

Although FLS is now considered an NHS service, the model did not originate as a formal NHS programme. The earliest structured version was developed in Glasgow in the late 1990s through collaboration between clinicians and the national osteoporosis charity, now the Royal Osteoporosis Society. Evaluation demonstrated reductions in secondary fractures, and the model was subsequently adopted and scaled across the NHS. Because implementation began locally rather than nationally, coverage remains uneven and referral pathways vary, affecting alignment with NICE guidance and BOAST trauma standards.

BOAST

The British Orthopaedic Association Standards for Trauma set out expectations for trauma and fracture care, including imaging quality, timelines for assessment and communication across teams.

For fragility fractures, BOAST standards are highly relevant because orthopaedic services are often the first clinical contact after a fracture. These standards emphasise documentation and communication with primary care and FLS teams.

Additional policy context

Royal College materials and NHS England toolkits highlight the importance of recognising vertebral fractures, improving radiology communication, and ensuring consistent transitions of care after a first fracture. Cochrane reviews summarise medication effectiveness, although evidence strength varies across drug classes. National reviews note challenges in monitoring requirements for long‑term osteoporosis therapies.

3. Pregnancy, postnatal and menopause contexts

Osteoporosis during pregnancy is rare, but case series describe vertebral fractures in the late antenatal or early postnatal period, particularly in women with very low BMI, nutritional deficiency or long‑term corticosteroid use. Due to low prevalence, evidence remains limited.

The menopause transition is a major pivot point in population risk. Declining oestrogen accelerates bone loss, and several national organisations recommend that bone health is considered when discussing menopausal symptoms. Investigations highlight variation in whether menopause care incorporates fracture‑risk assessment or clear information about long‑term skeletal health.

4. Investigations into lived experience

Investigations frequently highlight women reporting that back pain, height loss or rib pain were normalised or attributed to ageing, stress or posture. Vertebral fractures are often missed or identified incidentally on imaging but not consistently communicated or acted upon. Themes of diagnostic overshadowing arise particularly in women with multiple long‑term conditions.

Health‑inequality analyses show variation in access to bone‑health assessment among women from minority ethnic groups, disabled women and those with complex chronic illness.

Geographic variation in FLS coverage contributes to inconsistent pathways. Digital templates may omit relevant factors such as early menopause, steroid exposure or fall history, leading to underestimation of risk.

System watchpoints (for information only)

This section highlights system patterns seen in research, guidance and investigations. It is not medical or legal advice, and it is not a checklist for your own care.

Who the evidence represents

Much research focuses on older white women, leaving gaps for younger women, peri‑pregnancy presentations and women from diverse ethnic groups.

Imaging and reporting

Spinal fractures are common but frequently missed or not clearly communicated. Audits describe gaps in communication between radiology, orthopaedics and primary care.

BOAST adherence

BOAST standards emphasise timely assessment, accurate imaging and consistent communication. National reports note variability in how fragility fractures trigger bone‑health assessment.

Digital design

Risk calculators depend on accurate data entry. Missing information such as early menopause or steroid use may underestimate risk.

Transitions of care

Variation in FLS coverage leads to differences in follow‑up, treatment initiation and monitoring.

What is improving

• Expansion of FLS programmes in several regions.
• Updated NICE guidance providing clearer thresholds for assessment and treatment.
• Digital prompts for vertebral fracture identification within radiology systems.
• Early integration of bone health into some menopause pathways.
• Growing research into missed opportunities for secondary fracture prevention.

Where further improvement might come from

• More consistent implementation of BOAST standards for fragility fractures.
• National minimum standards for FLS coverage and staffing.
• Stronger communication systems across radiology, orthopaedics and primary care.
• Better representation of diverse women in osteoporosis research.
• Improved digital capture of key risk factors such as early menopause and steroid exposure.
Readers are invited to share evidence‑based ideas or examples of improvement by email. Please do not send personal data.

Reflective questions (off‑blog)

For clinicians

How reliably do fractures trigger referral into local FLS pathways?
How consistently are BOAST communication standards followed after fragility fractures?
What systems ensure incidental vertebral fractures are communicated and acted upon?
How well do digital templates capture menopause and medication‑related risk factors?
How are monitoring requirements for osteoporosis medication managed across services?

For patients and the public

How clearly is bone health discussed during menopause care?
Are fracture follow‑up pathways easy to understand?
How might communication about imaging results be improved?
Do appointment structures allow women to describe musculoskeletal symptoms fully?
What system factors make long‑term bone health harder to navigate?

Mandatory disclaimer

This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This project is independent and not a formal inquiry.

© 2026 Women’s Health Inquiry Project (WHIP). All written content is original research and may not be reproduced without permission. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.

References

NICE. Osteoporosis: assessing the risk of fragility fracture (CG146). 2023 update. Available at: https://www.nice.org.uk.
NICE. Osteoporosis: quality standard (QS149). 2017. Available at: https://www.nice.org.uk.
NHS England. Fracture Liaison Service Toolkit. Available at: https://www.england.nhs.uk.
British Orthopaedic Association. BOAST Guidelines. Available at: https://www.boa.ac.uk.
Royal Osteoporosis Society. Clinical Quality Hub. Available at: https://theros.org.uk.
Cochrane Bone, Joint and Muscle Trauma Group. Reviews. Available at: https://www.cochranelibrary.com.